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a b s t r a c t
Virus-like particles (VLPs) offer a platform to test the hypothesis that, since antibody binding to native
envelope glycoprotein (Env) trimers results in HIV-1 neutralization, that native Env trimers presented in
membranes may be useful for inducing neutralizing antibodies (nAbs) in a vaccine setting. So far, VLPs
have not fulﬁlled this potential. Here, using a “shotgun” approach, we evaluated a wide cross-section of
variables in a series of VLP immunizations. We identiﬁed 3 tentative leads. First, that VLP doses may not
have been sufﬁcient for optimal nAb induction. Second, that dampening the antigenicity of non-
functional Env (for example uncleaved gp160) using either protease digests or IgG masking may be
useful. Third, that guinea pig sera preferentially target non-conserved epitopes and exhibit relatively
high background activity, suggesting that rabbits may be preferable as small animal vaccine models.
Recent immunogenicity studies in rabbits appear to bear out all 3 of these leads.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Designing a vaccine for human immunodeﬁciency virus type 1
(HIV-1) remains a major challenge of modern biomedical research
(Schiffner et al., 2013). Broadly neutralizing antibodies (bnAbs) are
expected to be a key component of the protective immunity
imparted by an effective HIV-1 vaccine (Mascola and Monteﬁori,
2010). However, current vaccine candidates usually fail to elicit
effective tier 2 neutralization even against the vaccine strain – and
when they do so, it is usually elicited inconsistently in only a few
immunized animals and largely fails to cross-neutralize other tier
2 strains (Klasse et al., 2012; Mascola and Monteﬁori, 2010; McCoy
and Weiss, 2013; Schiffner et al., 2013; van Gils and Sanders, 2013).
HIV-1 neutralization occurs when antibodies bind to native,
functional Env spikes arrayed on viral membranes, thereby inter-
fering in their engagement with cellular receptors (Mascola and
Monteﬁori, 2010). Functional Env spikes consist of trimers of
gp120/gp41 heterodimers in which the surface gp120 subunit
mediates receptor binding and the membrane-anchoring gp41
subunit mediates fusion. These two subunits derive from a gp160
precursor that is glycosylated co-translationally (Earl et al., 1990),
and later processed by a furin-like enzyme to form native gp120/
gp41 trimers that are incorporated into nascent particles.
Mature Env spikes are compact and heavily glycosylated, thus
allowing them to evade antibody binding and neutralization
(Kwong and Mascola, 2012; Moore et al., 2006; van Gils and
Sanders, 2013). Env can exist in various other forms, including the
uncleaved (UNC) gp160 precursor, soluble monomeric gp120 and
gp41 stumps, all of which are relatively accessible to antibody
binding (Tong et al., 2012, 2013). It is perhaps not altogether
surprising then that vaccines based on these and other relatively
“accessible” forms of Env elicit antibodies that are largely unable
to penetrate the compact native trimer's natural defenses (Klasse
et al., 2012; Mascola and Monteﬁori, 2010; McCoy and Weiss,
2013; Schiffner et al., 2013). Conversely, the native Env trimer
itself, presented in its natural context on lipid membranes might
have the requisite stringency as an immunogen to consistently
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induce antibodies capable of penetrating its own highly sophisti-
cated defenses – if optimal immunization conditions can be
identiﬁed (Emini and Koff, 2004).
A natural lipid membrane context may be important for a fully
native Env trimer conformation. Considering that all currently
licensed vaccines against infectious diseases and several others
under development are particle-based, many of which incorporate
lipid membranes, this general approach has a strong track record
(Garrone et al., 2011; Kanekiyo et al., 2013; Kulkarni et al., 2012;
Kushnir et al., 2012; Roldao et al., 2010). Particle vaccines present-
ing native HIV-1 Env spikes have so far been explored in the form
of live inactivated viruses, VLPs, liposomes and virosomes (Bomsel
et al., 2011; Buonaguro et al., 2005; Chen et al., 2005; Crooks et al.,
2007; Dennison et al., 2011; Doan et al., 2005; Evans et al., 2005;
Grovit-Ferbas et al., 2000; Grundner et al., 2002; Hammonds et al.,
2003, 2005, 2007; Hicar et al., 2010; Kamdem Toukam et al., 2012;
Lifson et al., 2004; McBurney et al., 2007; McKenna et al., 2004,
2003; Montero et al., 2012; Pastori et al., 2012; Poon et al., 2005;
Visciano et al., 2011; Vzorov et al., 1999; Yang et al., 2012; Zhou
et al., 2011). However, none have yet demonstrated a great potential
to elicit tier 2 nAbs. One explanation for this lack of progress may be
that the native Env trimer's compact nature renders it an inherently
poor immunogen (see Fig. 4 in Tong et al. (2013)). It therefore
remains possible that higher native Env trimer doses and/or the use
of powerful dose-sparing adjuvants can address problem (Li et al.,
2006; VanCott et al., 1997).
Another problemwith particle-based vaccines is that they carry
non-functional Env on their surfaces, principally uncleaved (UNC)
gp160 and gp41 stumps that are relatively accessible to binding by
non-neutralizing antibodies and may therefore interfere with the
development of neutralizing responses to the native Env trimer
(Agrawal et al., 2011; Crooks et al., 2007; Hicar et al., 2010; Joyner
et al., 2011; Leaman et al., 2010; Moore et al., 2006; Nyambi et al.,
1998; Tong et al., 2012, 2013). One solution may be to extract and
purify soluble native Env trimers from membranes. However, this
is hampered by the instability of the isolated product and its
tendency to aggregate. Another solution may be to mask non-
functional Env using IgG. This idea has some precedents (Denisova
et al., 1996; Keller and Arora, 1999; Liao et al., 2004; Visciano et al.,
2008). Furthermore, IgG complexing may facilitate VLP adsorption
to follicular dendritic cells (Abdel-Motal et al., 2010; Forthal et al.,
2007; van Montfort et al., 2007) and antigen processing (Hioe et
al., 2009). A more recent option is to treat VLPs with proteases to
selectively digest and thereby remove non-functional Env, leaving
native Env trimers intact (Crooks et al., 2011; Tong et al., 2012).
A growing number of broadly neutralizing monoclonal anti-
bodies recovered from infected donors to date are considered to
be blueprints for vaccine discovery. Their sophisticated features,
however, raise questions about whether model species used for
vaccine testing have sufﬁcient germline immunoglobulin reper-
toire complexity to develop similar nAbs (Pinheiro et al., 2011).
This uncertainty calls for the continued testing of nAb vaccine
candidates in multiple animal models.
The goal in this study was to identify leads important for eliciting
tier 2 nAbs by VLP immunogens. Investigating all of the above-
mentioned variables would require very large animal numbers and
high costs. Here, using limited resources, and building on our previous
VLP immunogenicity study in guinea pigs (Crooks et al., 2007), as
outlined in Fig. 1, we examined a wide cross-section of variables in a
series of immunization studies in guinea pigs, macaques and rabbits to
try to partition factors that might associate with nAb development.
Our ﬁndings suggest that (i) higher VLP doses, (ii) dampening the
antigenicity of non-functional Env from VLP surfaces and (iii) the
preferential use of rabbits over guinea pigs as a small animal may be
important. All three of these leads appear to be validated in our more
recent VLP immunogenicity studies in rabbits.
Fig. 1. Overview of immunization parameters. Various immunization parameters, as indicated, were assessed in a shotgun approach to try to determine those that might
partition with nAb development. A consistent algorithm to analyze sera was used to enhance our ability to compare strategies between different immunization groups and
species.
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Results
Our previous VLP immunogenicity study in guinea pigs (group
G1 in Fig. 2 (Crooks et al., 2007)) resulted in weak and sporadic tier
2 neutralization of the JR-FL index virus. Here, we sought to
identify areas for improvement. Since our VLPs express native
Env trimers on their surfaces (Crooks et al., 2007, 2005, 2006;
Tong et al., 2012), we suggest that they should be capable of
consistently eliciting nAbs. A multitude of factors could, however,
limit the native trimer's immunogenicity, including an effective
dose, adjuvant, stability, immunogenic interference and the com-
petency of model species' immunoglobulin germline repertoires to
recognize this difﬁcult antigen.
A thorough investigation of the above parameters would require
large numbers of animals. Since our resources were limited, we used
a shotgun approach to investigate a wide cross-section of variables
to try to partition those associated with nAb development (Fig. 1).
Thus, we immunized a further group of guinea pigs (G2), three
groups of macaques (M1, M2 and M3) and two groups of rabbits (R1
and R2). Immunization studies were performed consecutively over a
number of years in the sequence shown in Fig. 2, with the exception
that the M3 macaques were immunized most recently. As informa-
tion accumulated, we built implicit improvements and tested new
parameters in each successive study. Thus, IgG masking strategies
differed between studies, as did adjuvants and other conditions.
Although our resources restricted us to only n¼3 animals per group
for guinea pigs and n¼2 for macaques, we were able to use n¼4
animals in rabbits and a thorough, harmonized serum analysis enabled
us to mine data for useful leads (Fig. 1).
Guinea pig VLP immunizations
Overview
A major goal of our G2 guinea pig immunization study was to
use IgG masking to prevent putative immunogenic interference by
non-functional Env on VLP surfaces (Fig. 1). Two protein A-puriﬁed
IgGs were isolated from the pooled sera of guinea pigs that were
immunized with SOS-VLPs (animals S9–S12 and P13–P15) or bald-
VLPs (animals P16–P18) in our previous G1 study (Fig. 2; Crooks
et al., 2007). VLP doses were estimated as described in Figs. S1
and S2. As shown in Fig. 2, G2 groups were stratiﬁed to receive
VLPs either alone or mixed with either of the two masking IgGs
above. One group (group V) received only SOS-VLP IgG (no VLPs)
as a control to monitor its decay.
At the time of the G2 study, we were concerned that the
detergent in Ribi adjuvant might destabilize VLPs and/or Env
trimers. To avoid this possibility, most G2 animals received VLPs
and Ribi at separate sites (Fig. 2, groups G2 II–V), in the hope that
Ribi's immune stimulatory effect alone would be sufﬁcient (i.e.
with no depot effect).
Fig. 3 shows a composite analysis of the two G1 masking IgGs,
G2 sera, two human HIV-1-infected donor (HIVþ) sera (1702 and
N160) and one HIV-1-seronegative serum (210). Fig. 3A shows
ELISA binding to various antigens, Figs. 3B and 3C show their
neutralizing activities and Fig. 3D shows competition with various
biotinylated mAbs in ELISA.
Guinea pig serum binding to JR-FL gp120, gp41 and bald-VLPs
HIV-1 donor sera 1702 and N160 bound strongly to gp120, gp41
and bald-VLPs (Fig. 3A). However, the uninfected donor serum 210
recognized none of these antigens. The G1 SOS-VLP IgG pool
bound strongly to gp120 and bald-VLPs, but not gp41, presumably
because major gp41 immunodominant epitopes are not exposed
on SOS-VLPs (Tong et al., 2013). The G1 bald-VLP IgG only reacted
with bald-VLPs, as expected (Fig. 3A). Most of the G2 sera bound
somewhat more weakly to gp120 and bald-VLPs than the G1 SOS-
VLP IgG pool, perhaps due to differences in dose and/or adjuvants
(Fig. 2). The marginal differences in binding titers between groups
G2-I and II (Fig. 3A), suggest that adjuvant co-formulation was not
Fig. 2. Summary of immunization studies. Seven immunization groups G1, G2, M1, M2, M3, R1 and R2 were coded according to species (i.e. G¼guinea pigs, M¼macaque and
R¼rabbit). Immunization studies were performed consecutively from top to bottom, starting from group G1, with the exception that the M3 study was performed last. In
each study, groups consisting of 2–6 animals were inoculated with the immunogens indicated. Env-VLP doses are expressed as an approximate gp120 equivalent dose
determined by ELISA (see Fig. S1). Gp120 equivalent dose/kg of average animal mass was calculated by assuming average masses as follows: guinea pigs (0.8 kg), rabbits
(4 kg) and macaques (6.5 kg). Total VLP p24 equivalent doses were estimated by SDS-PAGE-Western blot (Fig. S2). Adjuvants were either formulated with VLPs or
administered separately. In some groups (G2, M2 and R2), VLPs were complexed with masking IgG puriﬁed from the sera of animals of their respective preceding groups
(i.e. G1, M1 and R1). Control subgroups received only masking IgG (i.e. G2-V and R2-V). M3 animals received SOS-VLPs that were digested with proteases to remove
non-functional Env.
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crucial in this study. The lack of detectable binding in the G2-V
animals suggests that SOS-VLP IgG was diluted and/or decayed to
near background levels and therefore would not be expected to
contribute to the titers of responses generated in groups G2-III and
IV. In fact, SOS-VLP IgG masking completely blocked the develop-
ment of new gp120 responses and partially blocked bald-VLP
responses of group G2-III. Surprisingly, bald-VLP IgG masking
had less impact on titers of group G2-IV. HIV-1-infected donor
sera and VLP sera reacted strongly with 293T producer cells
(Fig. S3A), apparently due in large part to lipid reactivity (Fig. S3B).
Guinea pig serum neutralization
In Fig. 3B and C, we used various assays to detect nAbs. An
appraisal of JR-FL WT and SOS virus neutralization assays using
human TZM-bl and canine CF2 cells is shown in Figs. S4 and S5.
Brieﬂy, JR-FL SOS and WT viruses exhibit similar nAb sensitivities
(Fig. S5; Crooks et al., 2005). However, the TZM-bl assay is 5 fold
more sensitive, largely because of a “leave in” protocol rather than
the “wash out” protocol used in the CF2 assay (Fig. S4). The A328G
mutation renders the JR-FL isolate into a phenotype we term
“globally neutralization sensitive” (Fig. S5; Blish et al., 2008;
O'Rourke et al., 2009; Shen et al., 2010).
The various assays used in Fig. 3B and C provide a range
of sensitivities. The high sensitivity of the WT/TZM-bl format
(Fig. 3C) is reﬂected by the relatively high titers of HIVþ sera
1702 and N160 (compare Fig. 3B and C) and mAbs (Fig. S4A). WT/
TZM-bl activity was detected using the G1 SOS-VLP IgG pool and
by all the G2 VLP sera, except the G2-V control group (Fig. 3C).
However, none of the VLP sera neutralized the JR-FL SOS virus in a
more stringent washout format using CF2 target cells (Fig. 3B).
Puriﬁed G2 serum IgG exhibited nAb activity equivalent to the
parent sera, suggesting that the nAb activities in Fig. 3B and C are
IgG-mediated (data not shown). None of the sera neutralized the
Fig. 3. Proﬁle of puriﬁed G1 IgGs and G2 sera. (A) ELISA titers using recombinant JR-FL gp120, gp41 and bald-VLPs. Puriﬁed IgGs from pooled mixtures of SOS-VLP
(animals S9–S12) or bald-VLP (animals P13–P15) immune sera from our earlier G1 study are shown (Crooks et al., 2007). Data points are the arithmetic means of at least two
repeats. (B) Neutralization in the CF2 assay (Crooks et al., 2007), against the SOS parent virus, a “globally sensitive” SOS A328G mutant and SIVmac239 control virus, using a
“wash out” format. (C) Neutralization in the TZM-bl assay against JR-FL WT and SIVmac239 viruses, using a “leave in” format. All neutralization assays were performed at
least three times in duplicate. Arithmetic mean titers and standard deviations are shown. (D) Ability of pooled IgGs (0.5 mg/ml) and pooled group sera (1:20 dilution) to
inhibit the binding of various biotinylated mAbs to UNC SOS-VLPs in ELISA. Data are expressed as percentages, via the calculation: {(IC50 of biotin-mAb binding in the
presence of control prebleed serum)/(IC50 of biotin-mAb binding in the presence of competitor serum)}100. Each assay was repeated twice and showed similar
competition trends.
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SIVmac239 virus, thus ruling out non-speciﬁc activity (Fig. 3B, C).
In our previous report, bald-VLP sera exhibited some non-speciﬁc
nAb activity (Crooks et al., 2007). However, in the current study,
IgG puriﬁcation seems to have eliminated this problem (Fig. 3B, C).
As expected, all the G2 sera neutralized the globally sensitive
JR-FL mutant A328G mutant (Fig. 3B). The G1 SOS-VLP IgG pool
exhibited a higher titer, perhaps due to the use of a higher dose
and/or different adjuvants (Fig. 2).
A comparison of groups G2-I and G2-II suggests that adjuvant
co-formulation is not necessary (Fig. 3B, C), reﬂecting the similarly
comparable binding responses (Fig. 3A). SOS-VLP IgG masking led
to lower nAb titers in G2-III sera, perhaps because the weak nAbs
present in the G1 SOS-VLP masking IgG (Fig. 3C) partially blocked
de novo nAb development, just as they blocked gp120 binding
titers (Fig. 3A). In contrast, bald-VLP masking had little effect
(Fig. 3B, C). Representative neutralization assay titrations of serum
G2-12 (Fig. S6A) reveal dose-dependent neutralization in both the
WT/TZM-bl and A328G/CF2 assays. Weak, non-speciﬁc background
activity against SIV control viruses (Fig. S6A) was a common char-
acteristic of sera from this model species.
Guinea pig serum binding to native JR-FL Env trimer
Previously, we showed that native trimer binding in BN-PAGE
shifts tracks with neutralization (Binley et al., 2010, 2008; Crooks
et al., 2008, 2007, 2005, 2011; Kang et al., 2009; Moore et al.,
2006; Tong et al., 2012; Vaine et al., 2008). In Fig. S7A, some G2
sera, particularly the potent G2-1 serum, bound to the native Env
trimer. Pooled G2 group sera also bound convincingly to globally
sensitive JR-FL A328G Env trimers (Fig. 3B), as expected consider-
ing the potent neutralization of this virus (Fig. S7B).
Guinea pig serum mapping
Recently, we investigated mAb–mAb binding relationships on
VLP Env by ELISA (Tong et al., 2013), providing reference informa-
tion to interpret the competitive activities of our VLP sera in the
same assay. In Fig. 3D, each point represents serum competition
of a given mAb that may indicate either epitope overlap or a
conformational binding relationship. For simplicity, however, we
infer competitions to indicate overlaps.
Some symbols in Fig. 3D are coded in black or white to indicate
epitope clusters. The black symbols identify those that overlap the
CD4 and/or coreceptor binding sites (receptor cluster). The white
symbols identify those incorporating elements of the V3 loop
and N332 “super site” (V3 cluster) (Kong et al., 2013). Although
2G12 binding is N332-dependent, its speciﬁcity is unique, so it
was excluded from the latter cluster. 4E10 was used to represent
MPER mAbs.
Both HIV-1 donor sera (1702 and N160) competed quite
effectively with both the receptor and V3 clusters (Fig. 3D). Our
previous study suggests that competition of mAbs CO11, G3-42
and PGT121 but not 2G12 is best explained by V3 speciﬁcities (see
Fig. 8B in reference Tong et al. (2013)). 4E10-overlapping responses
were also strong. However, neither the 210 serum nor the G1 bald-
VLP IgG pool competed with any of the mAbs, conﬁrming the
speciﬁcity of this assay.
The G1 SOS-VLP pooled IgG competed effectively with the V3
cluster. However, competition with the receptor cluster mAbs was
somewhat weaker and little or no competition with either of mAbs
2G12 or 4E10 was observed (Fig. 3D; Crooks et al., 2007; Derby
et al., 2006). The G2-I, II and IV pooled sera showed somewhat
weaker competition than the G1 SOS-VLP pool (Fig. 3D). G2-III and
V serum competition was weak but still measureable (Fig. 3D), in
keeping with their weak binding (Fig. 3A). It may be inferred,
therefore, that the SOS-VLP masking IgG did not completely decay
in these animals. Unexpectedly, all G2 sera competed quite well
with mAb 4E10, but the G1 SOS-VLPs IgG pool did not.
Macaque VLP immunizations
Overview
VLP immunogenicity was evaluated in 10 rhesus macaques,
consisting of 2 groups of 4 animals, M1 and M2 and a third group,
M3, consisting of 2 animals (Fig. 2). Although cost and availability
precluded our use of greater animal numbers, we hoped to still
identify factors that partitioned with nAb development.
Macaque serum binding to JR-FL gp120, gp41 and bald-VLPs
At the time of the M1 study, we were still concerned about
possible adverse effects of adjuvant detergent, so we administered
VLPs and Ribi at separate sites. We initially compared the immu-
nogenicities of WT and SOS Envs. Three of the 4 M1 sera
recognized monomeric gp120 and bald-VLPs in ELISA, albeit at
modest titers (Fig. 4A). Gp41 titers were undetectable, except for
serum DV08, that lacked detectable gp120 binding, but recognized
gp41, albeit weakly (Fig. 3A). This serum also did not bind to bald-
VLPs and may therefore be considered as a non-responder.
In the M2 study, SOS-VLPs were co-formulated with Ribi. For
group M2-II, VLPs were also mixed with protein A-puriﬁed IgG
from SOS-VLP-immune M1 sera EN36 and EN37 (Fig. 2). Mean
gp120 and bald-VLP titers in the M2 study were higher than in the
M1 study. M2 sera also exhibited somewhat better binding to 293T
cells (Fig. S3A). However, IgG masking had little effect on serum
reactivity with gp120, bald-VLPs or 293T cells, perhaps because of
the weak antibody titers of the M1 sera that were used to make
the masking IgG (Fig. 4A; Fig. S3A).
In the M3 study, two macaques were immunized with protease
digested SOS-VLPs formulated in AS01B. The protease treatment
selectively clears non-functional Env, leaving the native Env trimer
intact (Crooks et al., 2011; Tong et al., 2012). The VLP dose in M3
animals (Fig. 2) was normalized to adjust for the modest overall
loss in mAb binding after protease digests (Tong et al., 2012).
Gp120 and bald-VLP titers were higher in the M3 sera than any
other group (Fig. 4A).
Macaque serum neutralization
In the WT/TZM-bl format, 5 of the 10 macaque sera exhibited
detectable neutralization (Fig. 4C). Serum 5514 was the most
potent and was also the only one to detectably neutralize in the
more stringent SOS/CF2 neutralization assay (Fig. 4B). As expected,
all 10 macaque sera neutralized in the A328G/CF2 format (Fig. 4B),
the 5514 serum yet again being the most potent. None of the sera
neutralized the control SIVmac239 virus. A sample neutralization
titration of serum CM84 is shown in Fig. S6B. Notably, all 4 sera
from macaques that received VLPs that were either masked by
SOS-VLP IgG (M2-II) or protease digested (M3) exhibited detect-
able nAbs in the WT/TZM-bl format, suggesting that these strate-
gies that were intended to refocus responses on the native trimer
may in fact be effective. The lack of nAbs in the EN36 and EN37
sera used to make the masking IgG may have been an important
factor in this partial success. The CM84 and CF48 sera both bound
to the native trimer binding in BN-PAGE (Fig. S8 and supplemen-
tary materials), as did both M3 sera (data not shown), consistent
with these nAb activities.
Macaque serum speciﬁcity mapping
All 10 macaque sera strongly competed with both the receptor
and V3 clusters, in many cases to saturation (Fig. 4D). Competition
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against V3 mAb CO11 was, however, relatively weak in the M1
sera. Unlike the guinea pig sera, the M2 sera, particularly subgroup
II, but not the M3 sera, competed with mAb 2G12. 4E10-competing
activity was present in all sera, particularly in the M3 animals,
despite the undetectable gp41 binding by ELISA (Fig. 4A).
Rabbit VLP immunizations
Rabbit study R1 serum analysis
At the time we initiated rabbit immunogenicity studies, we had
not yet developed protease digests as a means to eliminate non-
functional Env (Crooks et al., 2011) and IgG masking was still
our principle strategy for dealing with antigenic interference.
To try to optimize IgG masking, we considered the results of the
IgG masking attempts described above, which suggested that it
may be effective (M2 study), as long as the masking IgG is not
neutralizing (as in the G2 study). In an attempt to comprehen-
sively conceal non-neutralizing Env epitopes, while minimizing
nAb elicitation, we immunized R1 rabbits with recombinant gp120
monomer and gp41 in two groups of six animals. A further six
animals were immunized with bald-VLPs. All 3 immunogens were
co-formulated with AS01B (Fig. 2). Each R1 serum pool exhibited
high binding titers to their respective immunogens (Fig. 5A).
The neutralizing activity of the gp41 and bald-VLP serum pools
was undetectable (Fig. 5B, C). However, the R1 gp120 serum pool
neutralized weakly in the WT/TZM-bl and strongly in the A328G/
CF2 format (Fig. 5B, C).
The R1 gp120 serum pool overlapped with the receptor and V3
clusters, but not with 2G12 or 4E10 (Fig. 5D). The gp41 serum pool
overlapped the 7B2 and 2.2B epitopes (gp41 clusters I and II,
respectively), but not 4E10. As expected, the bald-VLP serum pool
Fig. 4. Proﬁle of M1 and M2 sera. Macaque sera were analyzed in an identical manner as the guinea pig sera described in Fig. 3.
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did not appreciably compete with any of the mAbs. In BN-PAGE
shifts, the R1 gp120 serum pool recognized the gp160 monomer
and the gp41 serum pool bound the gp41 stumps. However, none
of the serum pools appeared to bind the native Env trimer
(Fig. S9A).
Rabbit study R2 immunizations
R1 pooled IgGs were puriﬁed over protein A and were then
mixed with WT-VLP immunogens used for R2 rabbits (Fig. 2). A
control group (R2-V) received only masking IgG (no VLPs). AS01B
was used in groups I–V. Group VI received WT-VLPs co-formulated
with Adjuplex. An interim check of masking efﬁciency after the
second R2 immunization by BN-PAGE suggested that it was at least
partly effective (Fig. S9B).
Rabbit (R2) serum binding to gp120, gp41 and bald-VLPs
R2-I group sera exhibited lower mean gp120 and gp41 binding
titers than the R1 gp120 and gp41 serum pools (Fig. 5A). This was
not unexpected, given the lower antigenicity of VLPs Env com-
pared to soluble gp120 (Tong et al., 2013). In contrast, the bald-VLP
titers in group R2-I sera were similar to that of R1 bald-VLP serum
pool. Similar gp120 and bald-VLP mean ID50s in R2 groups I and II
were observed, although gp41 titers were slightly lower in group II,
consistent with some gp41 masking (Fig. 5A and S9B). Group R2-III
sera exhibited modestly higher gp120 and gp41 titers that may have
been augmented by bald-VLP IgG complexing. Bald-VLP ID50s were
similar, however, suggesting that masking was incomplete. R2-IV
serum gp120, gp41 and bald-VLP mean ID50s were similar to those
of R2-I, despite IgG masking. As expected, sera from R2-V animals
that received only masking IgG did not bind any of the antigens
Fig. 5. Proﬁle of R1 and R2 sera. Rabbit sera were analyzed as in Figs. 3 and 4, except that UNC WT-VLPs were used for competition mapping instead of UNC SOS-VLPs in
part D.
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effectively. The R2-VI animals that received WT-VLPs in Adjuplex
exhibited highly variable titers in individual animals. In two cases,
R2-22 and 24, gp120 titers were similar to those of the R2-I control
group, but in the other cases (R2-21 and 23), the titers were
substantially lower. Despite the apparent group-speciﬁc differences
observed above, Mann-Whitney tests did not suggest any statistical
signiﬁcance.
Rabbit (R2) serum neutralization
Most of the R2 sera exhibited no neutralization in either the
SOS/CF2 or WT/TZM-bl assays (Fig. 5B, C). Only two sera in
subgroup VI (animals 21 and 24) exhibited detectable nAbs. In
particular, serum R2-24 neutralized in both CF2 and TZM-bl assays
(Fig. S6C). It may not be a coincidence that this serum also strongly
bound all 3 antigens by ELISA (Fig. 5A). In contrast, serum R2-21
exhibited undetectable gp120 binding (Fig. 5A), yet neutralized in
the TZM/bl assay (Fig. 5C).
Most R2 sera exhibited A328G/CF2 titers of 1:1000, with no
obvious differences between groups (Fig. 5B). However, serum
R2-15 did not neutralize this virus, suggesting that it must target
epitopes that are unusually absent on these globally sensitive
trimers. None of the sera neutralized the SIVmac239 virus. We did
not detect any trimer binding by the R2 sera in BN-PAGE shifts,
except for serum R2-24 (not shown). Further BN-PAGE shifts
revealed that IgG masking did not block the development of new
responses to UNC gp160 (Fig. S9C, D).
Rabbit (R2) speciﬁcity mapping
Mapping of R2 serum group pools by ELISA (Fig. 5D) revealed
receptor and V3 cluster overlap by all VLP sera. Anti-gp120
masking led to somewhat weaker gp120 mAb competitions
(Fig. 5D; group IV sera and to some extent the group II). 7B2 and
2.2B competition was consistently high (Fig. 5D), regardless of
gp41 IgG masking or gp41 binding differences (Fig. 5A). All sera
except those of groups II and V competed with 4E10. Little or no
2G12 competition was detected. The somewhat weaker overall
competition by group VI serum pool than the group I serum pool
may be due to the different adjuvants used and/or to the weak
responses in some group VI sera (i.e animals 21 and 23).
Neutralization interference by monomeric JR-FL gp120 D368R
We next investigated the susceptibility of nAbs in our VLP sera
to soluble gp120 D368R monomer interference. This mutant gp120
does not bind cellular CD4 and therefore does not interfere with
infection. Fig. 6 shows that mAb 2G12 neutralization was blocked
by this gp120, but mAb b12 was unaffected because it does not
bind to the D368R mutant. The neutralizing activities of sera from
all 3 species were blocked by gp120 monomer. Thus, nAbs in these
sera recognize epitopes that are present on the gp120 monomer
and are impartial to the D368R mutation.
Inter-species VLP serum meta-analysis
To try to determine any useful patterns from the above studies,
we used a meta-analysis to mine our data. It is important to ﬁrst
acknowledge the caveat that this was a cross-sectional study in
which we used different VLP doses, different adjuvants, with or
without co-formulation, and various forms of IgG masking. Never-
theless, by comparing two variables at a time and ignoring all
others, we hoped to uncover the most important limitations of our
vaccine regimen.
We ﬁrst compared normalized VLP dose (Fig. 2) with mean nAb
titers of VLP immune sera from all 3 species (Fig. 7A). The trend in
Fig. 7A suggests higher normalized VLP doses correlates with
higher nAb titers. Higher VLP doses also correlated with higher
gp120 and bald-VLP binding titers (Fig. 7B and C). Furthermore,
higher gp120 binding titers correlated with higher WT/TZM-bl
titers (Fig. 7D). Overall, these data suggest that neither the binding
nor the neutralizing responses had reached an upper threshold,
due to our use of insufﬁcient VLP doses. These correlations appear
to be driven by the increased frequency and titer of nAbs in the
macaques and guinea pigs that received higher normalized doses
than the rabbits.
We next compared mean WT/TZM-bl ID50s and serum com-
petition of mAbs IgG1 b12 (Fig. 8A) and CO11 (Fig. 8B). The b12
and CO11 mAbs represent the receptor and V3 super site epitope
clusters (see Fig. 7B of Tong et al. (2013)). Despite their high gp120
binding and WT/TZM-bl neutralization titers (Fig. 7D), guinea pig
sera competed weakly with both b12 (Fig. 8A) and CO11 compared
to the sera from other model species (Fig. 8B). Guinea pig sera also
exhibited relatively low A328G/CF2 titers (Fig. 8C), suggesting poor
Fig. 6. Neutralization interference by monomeric JR-FL gp120 D368R. Neutralization assays were performed using the control mAbs b12 and 2G12 and the sera indicated, in
the presence or absence of added JR-FL gp120 D368R at an approximate concentration of 10 mg/ml. The WT/TZM-bl assay was used in each case except for serum 5514, in
which the SOS/CF2 assay was used.
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reactivity with known epitopes (most known mAbs to conserved
epitopes neutralize the A328G mutant effectively). Overall, this
suggests that guinea pig sera preferentially bind non-conserved
epitopes that do not overlap the receptor or V3 supersite clusters.
Thus, guinea pigs may not be ideal models for future attempts to
induce nAbs against conserved epitopes.
Finally, we examined the effect of the adjuvant used in
immunizations on serum nAb titers (Fig. S10). The only signiﬁcant
difference was between the Ribi and AS01B groups. However, this
may well be due to the relatively high normlaized dose used in
guinea pigs. Overall, we suggest that the adjuvant was not a
limiting factor in the current study and that the use of higher VLP
doses in macaques or rabbit models may in future be able to elicit
strong nAbs to conserved epitopes.
Discussion
We hypothesize that VLPs expressing native HIV-1 Env trimers
may be able to induce nAbs. However, one or more undeﬁned
factors may have so far limited their efﬁcacy as nAb-inducing
vaccines. These factors may include, but are not limited to,
immune interference by non-functional Env, uncertainties regard-
ing the effective dose, a need for an optimal adjuvant to compen-
sate for the inherently poor immunogenicity of the native Env
trimer, uncertainties regarding VLP stability in adjuvant formula-
tions, and inherent differences in model species to mount nAb
responses or to recognize conserved Env epitopes. A fundamental
and underappreciated problem in vaccine studies to date is that
autologous, vaccine-matched tier 2 nAbs tend to develop incon-
sistently only in a subset of vaccinated animals. In many cases, the
underlying cause appears to be that the immunogen insufﬁciently
resembles the native Env trimer and therefore largely elicits “off
target” responses. While this problem may be intractable for many
immunogens, it is eliminated for VLP immunogens because any
antibodies generated to the native trimer on their surfaces should
also neutralize. The present study tracks our attempts over several
years to identify any factor(s) that might limit the immunogenicity
of native trimers.
To accelerate the discovery process, we attempted to cover all
of the most likely factors (Fig. 1). However, a principle drawback
was that we were prevented from investigating all the parameters
comprehensively and with statistical strength both by our limited
access to large animal numbers and by our VLP production
capacity. We therefore evaluated a large cross-section of scenarios
in the hope of mining data to identify leads to prioritize in future,
statistically powered VLP immunogenicity studies. Our approach
in each animal group (Fig. 2) was based on our best ideas and
information available at the time of their initiation. Although each
study was self-inclusive and was not designed expressly for the
inter-study comparisons we undertook here, we used a consistent
algorithm to investigate all sera in the hope of making some
general observations. Despite the obvious drawbacks of our small
group numbers, we felt that this was a worthwhile compromise
compared to the alternative of evaluating few variables in larger
numbers of animals. A case in point is the general failure of our R2
Fig. 7. Relationship of normalized VLP dose with binding and neutralizing titers. The normalized VLP dose per animal mass was compared in a scatterplot against (A) WT
neutralization titer in TZM-bl assay; (B) gp120 binding titer in ELISA and (C) bald VLP binding titer in ELISA. (D) A scatterplot to show the correlative effect of gp120 binding
titer in all immunized animals and their respective WT neutralization titer by TZM-bl assay. Animals receiving IgG masking only (i.e. G2-V and R2-V) and the SOS-VLP IgG
masked group G2-III were excluded from this analysis.
Fig. 8. Relationship of serum speciﬁcity and neutralization titers. Serum pool competition of (A) b12 and (B) CO11 mAbs was correlated with WT/TZMbl ID50s. (C) Mean
serum group A328G/CF2 ID50s were correlated with WT/TZM-bl ID50s. Animals receiving IgG masking only (i.e. G2-V and R2-V) were excluded from this analysis.
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rabbit VLP immunizations, despite our use of n¼4 animals per
group, probably because our production capacity led us to use an
insufﬁcient VLP dose.
Consistent with our previous study (Crooks et al., 2007), VLP
immune sera, at best, only modestly neutralized the tier 2 JR-FL
autologous virus and did not neutralize other tier 2 isolates (not
shown). Nevertheless, we were able to identify some useful leads,
as follows. First, a post-hoc analysis unexpectedly suggested that
higher VLP doses correlate with higher nAb titers (Fig. 7). This
suggests that we may not have reached a threshold beyond which
higher doses would not induce more robust nAb titers. VLP dose
estimations are complicated by the fact that Env is only a minor
component. Furthermore, given the strong binding responses we
observed in our previous study (Crooks et al., 2007), we did not
anticipate dose as a possible limiting factor. Therefore the present
studies were not designed formally to test dose response.
The observations in Fig. 7 add to our growing realization that
immunogenicity might be governed by antigenic accessibility.
Since membrane-expressed Env is far less accessible to antibody
binding than soluble forms of Env like the gp120 monomer (Ota
et al., 2012; Tong et al., 2013), logically, it may also be less
immunogenic. Therefore, the common perception that particulate
antigens might have immunogenic advantages over their soluble
counterparts must be balanced by the reality that the forms of Env
presented on membranes are far more compact and therefore
probably less immunogenic. Thus, in Fig. 3, while the VLP doses
used may have been sufﬁcient to elicit binding responses, pre-
sumably against the moderately accessible non-functional Env
antigens on VLP membranes, higher doses might be necessary to
trigger responses to the more compact native trimer. We are
now evaluating various methods to improve VLP yield and native
trimer incorporation. This should facilitate an exploration of the
ability of higher VLP doses to induce nAbs. A limitation may be
that even with higher doses, IgG germline repertoires may limit
the frequency in which nAbs can be elicited. It may therefore be
useful to remove key glycans from the trimer to increase their
accessibility to germline precursors of broad nAbs (Hoot et al.,
2013; McGuire et al., 2013).
A second lead was that nAb development may be favored by
eliminating responses to non-functional Env. This was apparent in
two pairs of macaques that received either IgG masked VLPs or
protease digested “trimer VLPs”, all of which developed modest
nAbs (Fig. 4). IgG masking was not, however, effective in either
guinea pigs or rabbits. In both cases, the presence of nAbs in the
masking IgG could explain this failure. In the rabbits, this problem
may have been compounded by incomplete IgG masking and the
relatively low VLP dose. Our IgG masking strategy was launched as
the only practical approach to address the perceived problem of
non-functional Env interference at the time these studies were
initiated. However, in practice, it proved to be rather labor
intensive and difﬁcult to control. In some cases, masking may
have been insufﬁcient, especially after immunization, whereupon
the masking IgG becomes substantially diluted. Nevertheless, SOS-
VLP IgG masking completely prevented the development of bind-
ing responses in guinea pigs (Fig. 3A), despite not resulting in nAb
development in this instance. IgG masking efﬁciency could possi-
bly be improved by tailoring it to speciﬁcally mask only non-
functional Env, perhaps using VLPs that express only these forms
of Env (e.g. UNC-VLPs) in the ﬁrst round of immunizations.
Masking of non-Env VLP components by bald-VLP IgG had negli-
gible impact on nAb responses, suggesting that these responses
are independently regulated.
Protease digested “trimer VLPs” provided a far more convenient
solution for non-functional Env interference. This idea emerged
only recently and was therefore only tested in 2 macaques here
(group M3). The fact that both M3 macaques developed modest
titers was promising. However, we cannot rule out the possible
beneﬁts of the expanded immunization schedule and different
adjuvant used distinctly in the M3 group.
A third lead was that guinea pigs may not have great long term
potential as small animal vaccine models. Although detectable
nAbs were prevalent in guinea pig sera (Fig. 3C), this may be
largely a reﬂection of the relatively high normalized VLP dose they
received. A major concern was that guinea pig sera exhibited poor
competition with conserved CD4bs and V3 epitopes (Fig. 3D;
Fig. 8A, B), which was mirrored by their similarly weak A328G/
CF2 ID50s (Fig. 8C) and suggests a likely preoccupation with type-
speciﬁc epitopes. A further problem was a greater tendency for
non-speciﬁc neutralization by guinea pig sera, as exempliﬁed by
the effect of the G2-12 serum on SIVmac239 in the TZM-bl assay
(Fig. S6A). Rabbits may be preferable as small animal models (Pan
et al., 2013; Pinheiro et al., 2011) because they lack this serum
background problem and also react better with conserved targets
that may ultimately be important for the development of nAbs of
any breadth. However, it is important to point out that the VH
family diversity in both rabbits and guinea pigs is quite limited
compared to primates and that their antibody diversity is gener-
ated principally by gene conversion, contrasting with the largely
combinatorial origins of IgG diversity in primates (somatic hyper-
mutation is also used in all cases). Thus, the germline prototypes of
broad nAbs identiﬁed in HIVþ humans are unlikely to be relevant
in these small animal models, that will inevitably need to develop
species-speciﬁc solutions for generating antibodies that react with
the native trimer.
The effects of other immunization factors were less clear
(Fig. 1), perhaps because of the overriding effects of dose and
non-functional Env interference. Once the current limitations are
addressed, these other factors may be worth further study. For
example, contemporary adjuvants such as AS01B and Adjuplex
may be more effective than Ribi. Our concerns at the time of
our earlier immunogenicity studies here regarding the potential
destabilizing effects of Ribi and AS01B were more recently elimi-
nated experimentally (see Fig. 1 of Crooks et al. (2011)). Adjuplex
was, however, difﬁcult to evaluate, because its viscous nature
rendered it difﬁcult to separate from VLPs to evaluate what, if any,
effects it might have had on their integrity. However, the nAbs
observed in 2 of 4 rabbits (Fig. 5C) in which Adjuplex was used
suggest that it probably has no adverse effects.
A thorough and conservative approach was important to
conﬁrm the modest nAbs in our VLP sera. Thus, neutralization
(i) should be conﬁrmed in repeat assays, (ii) should ideally be
detectable in multiple neutralization assay formats, (iii) should not
neutralize control viruses (e.g. those bearing SIV Env), (iv) should
vary in potency in a dose-dependent manner with serum dilution,
(v) should be retained in IgG puriﬁed from sera, (vi) should ideally
be reﬂected by binding to the native Env trimer in BN-PAGE shift
assays (Crooks et al., 2005) and (vii) might also be adsorbed by
monomeric gp120. Of these approaches, the latter convincingly
demonstrated that serum neutralization was speciﬁcally adsorbed
(Fig. 8). This method also revealed that the neutralization in our
VLP sera did not depend either on quaternary Env trimer structure
or the D368 residue of the CD4 binding loop. The nAb titers were,
however, of insufﬁcient titer for detailed mapping efforts.
Several other assays centered on VLPs were developed to
comprehensively monitor the serum responses, to wit: bald-VLP
ELISAs, A328G neutralization and mapping studies. These assays
have the distinct advantages of matching the immunogens and
may be a useful part of a comprehensive serum analysis strategy to
mine our data.
When neutralization was absent, infection enhancement was
sometimes observed, (e.g. Fig. S6B; Fig. 6). SIV enhancement may
arise from the reactivity of sera with target cells (Fig. S3A) rather
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than with virus, which could affect cell growth and/or viability and
therefore the infection readout in neutralization assays.
Our observations that serum reactivity to bald VLPs is resistant
to protease digests (Fig. S3B) and that protease-digested VLPs also
induce high titer bald-VLP responses (Fig. 4A, M3 sera) suggest
serum reactivity to membrane lipids. Previously, in PBMC neutra-
lization assays, we observed robust non-speciﬁc neutralization by
VLP sera (see Fig. 6 in Crooks et al. (2007)), perhaps because lipid-
reactive serum antibodies trigger β-chemokine expression in
macrophages that block infection (Brown et al., 2007; Jobe et al.,
2012; Moody et al., 2010).
HIVþ donor sera appear to exhibit lipid reactivity similar to the
VLP sera (Fig. 3 and Fig. S3B; Fig. 9D of Crooks et al. (2007)). This
challenges the common perception that membrane lipid is immu-
nosilent and raises the question of why these responses develop
and whether they are safe. One explanation is provided by the
observation that enveloped viruses expose certain phospholipids
on their outer membrane leaﬂets, such as anionic phosphatidyl
serine that are normally sequestered on the inner leaﬂet of host
cell membranes (Jobe et al., 2012; Matyas et al., 2010; Soares et al.,
2008; Lorizate et al., 2013). These lipids are ﬂipped “inside out” in
a scrambling effect induced by cancer, inﬂammation, or infection
(Sims and Wiedmer, 2001) and commonly induce antibodies
as part of the array of early immune responses. The lack of any
adverse effects of VLP immunizations and the similar lack of
problems with other licensed vaccines that incorporate lipid
membranes, such as those for inﬂuenza and hepatitis B, suggest
a good safety proﬁle. Lipid antibodies are, in fact, benign and
ubiquitous in nature (Alving, 2006, 2008; Jobe et al., 2012; Matyas
et al., 2010). The expression of these unusual lipids on permanent
(i.e. cancerous) cell lines could explain their staining by our VLP
sera (Fig. S3A).
The 4E10 epitope overlap by many VLP sera was unexpected
(Figs. 3–5), especially given the low gp41 binding titers in guinea
pigs and macaques (Figs. 3 and 4). The particularly strong 4E10
competition by M3 sera could be partly result of the 10-fold
increase in MPER epitope exposure following protease digestion of
VLPs (Tong et al., 2012). On the other hand, the gp120 interference
of M3 sera suggests that MPER nAbs do not contribution to
neutralization (Fig. 6). The possibility that VLP-elicited anti-lipid
antibodies non-speciﬁcally compete with 4E10 appears to be ruled
out because bald-VLP sera do not compete (Figs. 3 and 5).
In summary, our shotgun approach to discover factors impor-
tant for nAb induction by VLP immunogens suggested that higher
VLP doses and removing interference by non-functional Env may
be worth testing, preferably in rabbit models. Indeed, in studies
conducted since the work described here, we have observed
potent autologous tier 2 nAbs (WT/TZM-bl titers of 1:1000) in
two of 8 rabbits immunized with a high dose (4150 mg/kg) of
protease-digested trimer VLPs. However, little or no nAbs were
observed in 4 guinea pigs immunized with a similar high dose of
trimer VLPs. Furthermore, no nAbs were observed in 4 rabbits
immunized with a high dose of undigested VLPs. These ﬁndings
appear to validate the leads we identiﬁed here. The continued use
of our algorithm to characterize VLP sera should allow us to track
factors important for further improving nAb responses in the
future.
Materials and methods
Monoclonal antibodies
Monoclonal antibodies (mAbs) were obtained from their pro-
ducers, the NIH AIDS reagent repository, or commercial suppliers.
They included the following (originators in parentheses): 17b and
E51 (J. Robinson), directed to CD4-inducible (CD4i) epitopes of
gp120 (Labrijn et al., 2003; Xiang et al., 2002); 2G12 (H. Katinger),
directed to a glycan-dependent epitope of gp120 (Sanders et al.,
2002; Scanlan et al., 2002); F2A3, CO11, 39F (J. Robinson), directed
to the gp120 V3 loop (Crooks et al., 2005); PGT121 (D. Burton),
directed to an N332-dependent gp120 epitope (Walker et al.,
2011); G3-42 (M. Fung), directed to a C4-V3 epitope (Moore
et al., 1994, 1993; Sun et al., 1989); b6, b12 (D. Burton), and 15e
(J. Robinson), directed to the CD4 binding site (CD4bs) (Burton
et al., 1994); 2F5 and 4E10 (H. Katinger), directed to the gp41
membrane-proximal ectodomain region (MPER) (Huang et al.,
2012; Zwick et al., 2004); 7B2 and 2.2B, directed to the gp41
cluster I and II epitopes, respectively (Moore et al., 2006).
Recombinant Env glycoproteins, soluble CD4 and p24
Recombinant monomeric JR-FL gp120 and soluble CD4 (sCD4),
consisting of all the 4 outer domains were gifts from Progenics
Pharmaceuticals (Tarrytown, NY). Recombinant HXB2 gp41 (Cata-
log#VTI310; residues 546-682) was obtained from Meridian
Life Science (Saco, Maine). Recombinant p24 was purchased from
ProSpec-Tany TechnoGene Ltd. (Israel).
Antisera and HIVþ donor plasmas and HIVIG
The HIV-1-infected donor plasmas 1702, N160, BB68, 1686 and
an uninfected control (donor 210) were described previously
(Binley et al., 2008; Crooks et al., 2005). HIVIG was obtained from
J. Mascola (NIH). Since these specimens were not generated
speciﬁcally for this study, the Torrey Pines Institutional Review
Board (IRB-12-001-JB) waived informed consent.
Plasmids and mutagenesis
The JR-FL clone was used as our parent Env (Binley et al., 2003;
Crooks et al., 2007, 2005, 2011; Moore et al., 2006; Tong et al.,
2012, 2013), as it expresses well and exhibits efﬁcient gp120/gp41
processing. The pCAGGS plasmid was used to express various
mutants (Binley et al., 2003; Moore et al., 2006), all with a gp41
tail truncation (gp160ΔCT) that leads to higher expression without
signiﬁcantly affecting neutralization sensitivity compared to full
length Env (Crooks et al., 2005). Mutants were generated by
Quikchange (Agilent Technologies) and numbered according to
the HXB2 reference strain (Binley et al., 2008). “SOS” mutations
introduce an intermolecular disulﬁde between gp120 and gp41
(Binley et al., 2003, 2000; Crooks et al., 2005). The A328G
mutation increases neutralization sensitivity to nAbs as well as
non-nAbs (Tomaras et al., 2011). The double mutant K510S/R511S
ablates gp120–gp41 processing, resulting in uncleaved gp160
(UNC) (Crooks et al., 2011). Env-deﬁcient sub-genomic plasmids
pNL4-3.Luc.R-E- and pSG3ΔEnv were described previously (Binley
et al., 2002; Li et al., 2005). A JR-FL gp120 D368R mutant was made
in the PPI4 plasmid (Binley et al., 2000).
VLP production
WT-VLPs, SOS-VLPs, or UNC-VLPs were produced by co-
transfecting 293T cells with pNL4-3.Luc.R-E- and pCAGGS-based
Env-expressing plasmids, as described previously (Tong et al.,
2012). “Bald-VLPs” formerly termed “naked VLPs” (Crooks et al.,
2007) bearing no Env were produced by transfecting pNL4-3.Luc.
R-E- alone. VLPs were inactivated using 1 mM aldrithiol (AT-2)
(Rossio et al., 1998) and in some cases, were digested with a
protease cocktail including proteinase K, subtilisin, chymotrypsin
and trypsin, as described previously (Tong et al., 2012).
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Animal immunizations
Species
Dunkin Hartley guinea pig and New Zealand white rabbit
immunizations were performed at the Pocono Rabbit Farm
(Canadensis, PA). Rhesus macaque immunizations were performed
at the Tulane University Primate Center or Bioqual Inc (Rockville,
MD). These sites are approved by the Association for Assessment
and Accreditation of Laboratory Animal Care. All animals were fed,
housed and handled in strict accordance with the recommenda-
tions of the NIH Guide for the Care and Use of Laboratory Animals
and the Animal Welfare Act. Macaques were housed indoors in
stainless steel cages, had a 12 h/12 h daily light cycle, were fed
twice daily, provided water ad libitum, and were given various
toys and feeding enrichment.
Immunization protocols were approved by all Institutional
Animal Care and Use Committees (protocols TPI 10-03, TPI 13-01
and Tulane 3309), for which Animal Welfare Assurance numbers are
A4193-01 (Torrey Pines Institute), A4499-01 (Tulane University
Primate Center), A-3086-01 (Bioqual) and A3886-01 (Pocono Rabbit
Farm and Laboratory). For all immunization and bleed protocols,
pain and distress was slight and momentary and did not affect
animal health. Discomfort and injury to animals was limited to that
which is unavoidable in the conduct of scientiﬁcally valuable
research. Analgesics, anesthetics, and tranquilizing drugs were used
as necessary by veterinary staff. For macaques, ketamine (10 mg/kg)
was administered intramuscularly as an anesthesia to immobilize
animals for all procedures. Macaque health was monitored by
complete physical examinations under ketamine anesthesia before
each immunization and bleed.
Rabbits and guinea pigs were all female. Macaques were all
male. Immunization routes were intramuscular (IM), intradermal
(ID) and subcutaneous (SC), as indicated in Fig. 2. Each animal was
immunized 3 times, at 6 week intervals. An exception was the
macaque M3 group who received VLPs at months 0, 1 and 6. Final
sera were collected 2 weeks after the 3rd immunization. At
the end of each study, rabbits and guinea pigs were euthanized
according to NIH guidelines by administering ketamine and
xyalzine intramuscularly at 35 mg/kg and 5 mg/kg, respectively,
followed by exsanguination via cardiac puncture. Macaques were
returned to the colony.
Immunogens
Immunogens included WT-VLPs, SOS-VLPs, bald-VLPs, recom-
binant JR-FL gp120 and HXB2 gp41. Some animals were immu-
nized with VLPs mixed with polyclonal IgG or with polyclonal IgG
alone (e.g. guinea pig groups G2-III and G2-V, respectively,
in Fig. 2). This polyclonal IgG was isolated by protein A-agarose
chromatography (GE Healthcare) from the immune sera of an
initial round of immunizations. It was then adjusted to 10 mg/ml
to approximately match the IgG concentration of the parent sera.
For animals receiving VLP–IgG complexes, VLP pellets were resus-
pended in puriﬁed serum IgG and incubated for 1 h at room
temperature (RT). Macaque group M3 animals received “SOS
trimer VLPs” that had been protease digested to clear non-
functional Env (Fig. 2). Total immunogen volumes were 0.3 ml
for guinea pigs and 0.5 ml for rabbits and macaques. When more
than one type of masking IgG was used (e.g. group R2-II), total
immunogen volumes comprised of equal volumes of each 10 mg/ml
IgG stock.
Adjuvants
Adjuvants included the CpG-based adjuvant ImmunEASY
(Qiagen), Quillaja saponaria-derived QS21, the Ribi adjuvant
system (Ras3C) (Sigma), Adjuplex (Advanced BioAdjuvants) and
AS01B (GlaxoSmithKline). Ras3C is a 2.0% v/v squalene oil-in-
water emulsion containing 40monophosphoryl lipid A (MPL)
derived from the lipopolysaccharide of Salmonella minnesota
R595, cell wall skeleton from Mycobacterium phlei and synthetic
trehalose dicorynomycolate. Adjuplex consists of detergent-free
lecithin and carbomer homopolymer. AS01B consists of liposomes
containing deacylated MPL and QS21. In most cases, adjuvants and
immunogens were co-formulated. However, in some cases were
administered separately (Fig. 2).
Dose
Gp120 and gp41 were administered in 100 mg doses. Doses of
the Env component of VLPs were estimated in terms of “gp120
equivalents” by ELISA (see below). Immulon II plates were coated
overnight at 4 1C with graded dilutions of monomeric gp120 or
Env-VLPs. Following a PBS wash and blocking, a panel of mAbs
were titrated against each antigen. Alkaline phosphatase anti-Fc
conjugates (Accurate, Westbury, NY) and solubilized SigmaFAST
p-nitrophenyl phosphate tablets (Sigma) were then used to detect
binding. Plates were read at 405 nm.
VLP Gag p24 doses were determined in reference to a recom-
binant p24 standard by reducing SDS-PAGE-Western blots that
were probed ﬁrst by HIVIG diluted to 1 mg/ml in PBS containing 2%
nonfat milk, then by an alkaline phosphatase-labeled anti-human
Fc conjugate (Jackson) and ﬁnally developed using SigmaFast BCIP/
NBT (5-Bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazo-
lium) substrate (Sigma). Band densities were quantiﬁed using NIH
Image software.
Serum analysis
ELISA
Gp120, gp41 and bald-VLPs. Immulon II plates were coated
overnight at 4 1C with recombinant gp120 or gp41 at 5 mg/ml.
Bald-VLPs were coated at 20 their concentration in transfection
supernatants. In some experiments, bald-VLPs were protease-
digested (Tong et al., 2012). Species-matched anti-Fc conjugates
were used to detect serum binding. The serum dilution resulting in
an OD of 0.5 (5 times background) was recorded as its titer. Each
assay was performed at least three times.
Binding speciﬁcity. In competitive VLP ELISAs (Tong et al., 2013),
pooled serum groups at a 1:20 dilution were used to inhibit the
binding of graded concentrations of biotinylated mAbs to VLPs
coated at 20 on ELISA wells. A prebleed was used as a control
competitor. MAbs were biotinylated using NHS-X-biotin reagent
(Calbiochem). Soluble CD4 was used at 2 mg/ml. Biotinylated mAb
binding was detected using streptavidin-alkaline phosphatase
(Vector, Burlingame, CA). Competition was expressed as a percentage
relative to biotinylated mAb binding in the presence of the prebleed
control.
Neutralization assays
Neutralization assays were performed at least 3 times in duplicate
to ensure consistency.
CF2.CD4.CCR5 assays
Virus was incubated with graded dilutions of antibody for 1 h
at 37 1C and then added to CD4.CD4.CCR5 cells (CF2 for short),
incubated for 2 h at 37 1C, after which the medium was changed.
For SOS viruses, infection was activated by adding 5 mM DTT for
5 min, followed by a PBS wash and the addition of fresh medium.
This is termed the “wash out” format. After 3 days, luciferase
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activity was measured in cell lysates, as described previously
(Crooks et al., 2005).
TZM-bl assays
Two versions of a neutralization assay using human cervical
HeLa-derived TZM-bl cells (CD4 and CCR5 positive) were used
(1) a standard or “leave in” format (Li et al., 2005), in which
trypsinized TZM-bl cells were added to virus–antibody mixtures
and left for 3 days without a change of medium and (2) a “wash
out” format in which virus–antibody mixtures were added to wells
pre-seeded with TZM-bl cells and the mediumwas changed after a
2 h incubation at 37 1C. Three days later, luciferase activity was
measured in lysates.
Gp120 interference
Monomeric JR-FL gp120 D368R was made by transfecting 293T
cells with a PPI4-based plasmid and were puriﬁed over Galanthus
nivalis-agarose then added to neutralization assays at 10 mg/ml.
Blue native PAGE (BN-PAGE) shift assays
BN-PAGE “shift” assays were used to measure the ability of
antibodies to bind VLP Env (Crooks et al., 2008, 2007, 2005; Moore
et al., 2006). Brieﬂy, VLPs were incubated with antibody for 1 h at
37 1C, then washed with PBS, solubilized in 0.12% Triton X-100,
loaded onto a 4–12% Bis-Tris NuPAGE gel (Life Technologies, Inc.)
and separated at 4 1C for 3 h at 100 V. Ferritin (GE Healthcare) was
used as a size standard. Gels were blotted onto polyvinylidene
diﬂuoride membranes, destained, immersed in blocking buffer (4%
nonfat milk in PBS) and probed by mAbs 2G12, b12, 39F, 2F5 and
4E10 at 1 mg/ml each. When WT-VLPs were used, this mAb cocktail
was supplemented with mAbs 7B2 and 2.2B. Blots were then probed
by an anti-human Fc alkaline phosphatase conjugate (Jackson) and
developed using SigmaFast BCIP/NBT substrate (Sigma). Binding was
then assessed by the loss of the unliganded trimer density as it
forms complexes with nAbs, using NIH Image software.
Flow cytometry
293T cells were incubated with sera for 1 h at RT. FITC-labeled
species-speciﬁc anti-Fc conjugates (Jackson) were used for detection.
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